Quidelortho Corp
QDEL.OQ- Latest Trade
- trading lower87.2USD
- Change
- -3.8
- % Change
4.18%Negative
- As of Aug 12 2022. Values delayed up to 15 minutes
- Day Range
- 87.13 - 91.65
- 52-Week Range
- 85.44 - 180.00
- Previous Close
- 91.00
- Open
- 91.58
- Volume
- 271,884.00
- 3 Month Average Trading Volume
- 15.75
- Shares Out (Mil)
- 66.95
- Market Cap
- 6,092.72
- Forward P/E
- 5.87
- Dividend Yield
- -99,999.99
Key Statistics
2.33333333 mean rating - 6 analysts
- P/E Excl. Extra Items (TTM)
- 4.21
- Price To Sales (TTM)
- 2.21
- Price To Book (Quarterly)
- 1.24
- Price To Cash Flow (Per Share TTM)
- 5.56
- Total Debt/Total Equity (Quarterly)
- 55.72
- Long Term Debt/Equity (Quarterly)
- 51.49
- Return On Investment (TTM)
- 21.14
- Return On Equity (TTM)
- 18.93
2021 (millions USD)
About Quidelortho Corp (QDEL.OQ)
Company Information
QuidelOrtho Corporation is a vitro diagnostics company. The Company is engaged in the development and manufacturing of advanced technologies in diagnostic testing. Its product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and a range of clinical and at-home products to detect COVID-19. The Company’s capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, molecular assay development, lab-based in vitro diagnostics, blood bank solutions and transfusion pre-screening. Its product categories include visually-read lateral flow, direct fluorescent antibodies, micro-titer production, fluorescent immunoassay products, molecular diagnostic products including its flagship Savanna, immunodiagnostics and integrated testing systems, pre-transfusion testing, immunodiagnostic donor screening systems and services, and ortho care services and informatics.
Address
9975 Summers Ridge RoadSAN DIEGO, CA
92121
United States
Industry
Healthcare Facilities
Executive Leadership
- Kenneth F. Buechler
- Independent Chairman of the Board
- Douglas C. Bryant
- President, Chief Executive Officer, Director
- Randall J. Steward
- Chief Financial Officer
- Robert Joseph Bujarski
- Chief Operating Officer
- Michelle A. Hodges
- Senior Vice President, General Counsel
- William J. Ferenczy
- Senior Vice President - Cardiometabolic Business Unit
- Karen C. Gibson
- Senior Vice President - Digital Health Business Unit
- Werner E. Kroll
- Senior Vice President - R&D
- Tamara A. Ranalli
- Senior Vice President - Molecular Business
- Edward Keith Russell
- Senior Vice President - Business Development
- Edward L. Michael
- Independent Director
- Mary Lake Polan
- Independent Director
- Ann D. Rhoads
- Independent Director
- Matthew W. Strobeck
- Independent Director
- Kenneth Jon Widder
- Independent Director
- Joseph D. Wilkins
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,799.70 | 0.56%Positive |
| Copper | 676.30 | 0.70%Negative |
| Brent Crude Oil | 97.85 | 1.76%Negative |
| CBOT Soybeans | 1,691.50 | 1.05%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,272.06 | 1.54%Positive |
| Euro STOXX 50 | 3,776.81 | 0.53%Positive |
| FTSE 100 | 7,500.89 | 0.47%Positive |
| Nikkei 225 | 28,546.98 | 2.62%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes